Effect of monophosphoryl lipid A on host resistance to bacterial infection.
The ability of monophosphoryl lipid A (MPLA) to enhance nonspecific host resistance to bacterial infections was studied. Mice were treated with MPLA prior to intraperitoneal challenge with Escherichia coli or Staphylococcus epidermidis. Animals received additional MPLA for 2 days postinfection, and survival rates were determined. Ten micrograms of MPLA per mouse significantly improved the survival of animals infected with either bacterial species. Dose-response studies showed significant MPLA-induced protection at doses of 6 micrograms/kg against E. coli challenge and 60 micrograms/kg against S. epidermidis challenge.
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000818:Animals; D001424:Bacterial Infections / Q000276:immunology*; D004305:Dose-Response Relationship, Drug; D008050:Lipid A / Q000031:analogs & derivatives* / Q000627:therapeutic use; D051379:Mice
D000276:Adjuvants, Immunologic; D008050:Lipid A; C048436:monophosphoryl lipid A